Can you take Bronkosol with Ivosidenib?

The isoetharine in Bronkosol has a moderate potential interaction with Diabetes Mellitus.

Adrenergic bronchodilators may cause increases in blood glucose concentrations. These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended. Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis. Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.

The isoetharine in Bronkosol has a moderate potential interaction with Heart Disease.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Ivosidenib has a moderate potential interaction with Heart Failure.

Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-hydroxytryptamine-3 [5-HT3] receptor antagonists) and CYP450 3A4 inhibitors may increase the risk of QTc interval prolongation. ECGs and electrolytes should be monitored. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted if QTc increases to greater than 480 and less than 500 msec. Ivosidenib should be interrupted and the dosage should be reduced if QTc increases to greater than 500 msec. Ivosidenib should be permanently discontinued in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.

The isoetharine in Bronkosol has a moderate potential interaction with High Blood Pressure.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

The isoetharine in Bronkosol has a moderate potential interaction with Hyperthyroidism.

Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression). Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol. However, beta-2-selectivity is not absolute and can be lost with larger doses. High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias. Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension. The recommended dosages should not be exceeded.

Ivosidenib has a moderate potential interaction with Hypocalcemia.

Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-hydroxytryptamine-3 [5-HT3] receptor antagonists) and CYP450 3A4 inhibitors may increase the risk of QTc interval prolongation. ECGs and electrolytes should be monitored. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted if QTc increases to greater than 480 and less than 500 msec. Ivosidenib should be interrupted and the dosage should be reduced if QTc increases to greater than 500 msec. Ivosidenib should be permanently discontinued in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.

The isoetharine in Bronkosol has a moderate potential interaction with Hypokalemia.

Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration. Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects. The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown. Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.

Ivosidenib has a moderate potential interaction with Hypokalemia.

Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-hydroxytryptamine-3 [5-HT3] receptor antagonists) and CYP450 3A4 inhibitors may increase the risk of QTc interval prolongation. ECGs and electrolytes should be monitored. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted if QTc increases to greater than 480 and less than 500 msec. Ivosidenib should be interrupted and the dosage should be reduced if QTc increases to greater than 500 msec. Ivosidenib should be permanently discontinued in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.

Ivosidenib has a moderate potential interaction with Hyponatremia.

Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-hydroxytryptamine-3 [5-HT3] receptor antagonists) and CYP450 3A4 inhibitors may increase the risk of QTc interval prolongation. ECGs and electrolytes should be monitored. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted if QTc increases to greater than 480 and less than 500 msec. Ivosidenib should be interrupted and the dosage should be reduced if QTc increases to greater than 500 msec. Ivosidenib should be permanently discontinued in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.

Ivosidenib has a moderate potential interaction with Liver Disease.

The pharmacokinetics and safety of ivosidenib in patients with severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2, Modification of Diet in Renal Disease [MDRD]), renal dysfunction requiring dialysis, or severe liver dysfunction (Child-Pugh C) are unknown. The risks and potential benefits should be considered before starting ivosidenib in patients with preexisting severe renal dysfunction, preexisting severe liver dysfunction, or who are requiring dialysis. Caution is advised in these patients.

Ivosidenib has a moderate potential interaction with Long QT Syndrome.

Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-hydroxytryptamine-3 [5-HT3] receptor antagonists) and CYP450 3A4 inhibitors may increase the risk of QTc interval prolongation. ECGs and electrolytes should be monitored. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted if QTc increases to greater than 480 and less than 500 msec. Ivosidenib should be interrupted and the dosage should be reduced if QTc increases to greater than 500 msec. Ivosidenib should be permanently discontinued in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.

Ivosidenib has a moderate potential interaction with Magnesium Imbalance.

Patients treated with ivosidenib can develop QTc prolongation and ventricular arrhythmias. Concomitant use of ivosidenib with drugs known to prolong the QTc interval (e.g., antiarrhythmic medicines, fluoroquinolones, triazole antifungals, 5-hydroxytryptamine-3 [5-HT3] receptor antagonists) and CYP450 3A4 inhibitors may increase the risk of QTc interval prolongation. ECGs and electrolytes should be monitored. In patients with congenital long QTc syndrome, congestive heart failure, or electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary. Treatment should be interrupted if QTc increases to greater than 480 and less than 500 msec. Ivosidenib should be interrupted and the dosage should be reduced if QTc increases to greater than 500 msec. Ivosidenib should be permanently discontinued in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia.

Ivosidenib has a moderate potential interaction with Renal Dysfunction.

The pharmacokinetics and safety of ivosidenib in patients with severe renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2, Modification of Diet in Renal Disease [MDRD]), renal dysfunction requiring dialysis, or severe liver dysfunction (Child-Pugh C) are unknown. The risks and potential benefits should be considered before starting ivosidenib in patients with preexisting severe renal dysfunction, preexisting severe liver dysfunction, or who are requiring dialysis. Caution is advised in these patients.

The isoetharine in Bronkosol has a moderate potential interaction with Seizures.

Adrenergic bronchodilators may cause CNS stimulation. Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders. Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.